Xumed Pharmaceuticals Private Limited
Founded in 2019 and headquartered in Uttar Pradesh, India.
2019 | Lucknow, Uttar Pradesh (India) | Active
Xumed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth 7.54%
- Ebitda 7.54%
- Net Worth -1.72%
- Total Assets -4.78%
About Xumed Pharmaceuticals
Xumed Pharmaceuticals Private Limited (XPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 October 2019 (Five years and four months 16 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shailendra Mandal and Nitika Yadav serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299UP2019PTC122256
- Company No.
122256
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2019
- Date of AGM
27 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Chemicals
Who are the key members and board of directors at Xumed Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailendra Mandal  | Director | 04-Apr-2023 | Current |
| Nitika Yadav | Director | 04-Apr-2023 | Current |
Financial Performance of Xumed Pharmaceuticals.
Xumed Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 7.54% increase in profit. The company's net worth dipped by a decrease of 1.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xumed Pharmaceuticals?
Unlock access to Xumed Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xumed Pharmaceuticals?
Unlock and access historical data on people associated with Xumed Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xumed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xumed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
